Voyager Therapeutics, Inc. 8-K

What Happened

• Voyager Therapeutics, Inc. (ticker: VYGR) announced its first quarter 2026 financial results and provided corporate updates on May 7, 2026. The company furnished the full press release as Exhibit 99.1 to its Current Report on Form 8-K (filed 2026-05-07), which is incorporated by reference into the filing. The 8-K item reported is Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 7, 2026 (Form 8-K, Accession 0001104659-26-057115).
• Item reported: 2.02 — Results of Operations and Financial Condition (press release furnished as Exhibit 99.1).
• Exhibit: 99.1 — press release with the company’s Q1 2026 financial results and corporate updates (incorporated by reference).
• The filing also lists Item 9.01 (Financial Statements and Exhibits) to include the press release exhibit.

Why It Matters

• Quarterly results and corporate updates can affect investor expectations for revenue, cash runway, and development progress; this 8-K signals material quarterly information is now public.
• Retail investors should read the attached press release (Exhibit 99.1) for the specific earnings, revenue, and operational figures, and watch for any follow-up filings (e.g., 10-Q) or investor calls that provide further detail.
• If you hold or watch VYGR, consider reviewing the press release and the company’s investor-relations materials to understand implications for guidance, liquidity, and program timelines.